Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02719184 · ClinicalTrials.gov registry record
Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 463
- Enrollment target
NCT02719184 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 463 participants.
The verdict
NCT02719184 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 463 participants
- Enrollment target
Study Summary
The study will include 60 healthy subjects (ex-smoker without any airflow limitation), 125 COPD GOLD (global initiative for chronic obstructive lung disease) I , 125 COPD GOLD II, 125 COPD GOLD III and up to 20 patients with COPD and A1AT (Alpha1-Antitrypsin) deficiency (ZZ genotype). Soluble and imaging biomarkers will be investigated addressing different aspects of disease pathways postulated to be relevant for COPD progression.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 463 participants |
| Start Date | 2016-04-13 |
| Est. Completion | 2021-06-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02719184
The ClinicalTrials.gov registry entry for NCT02719184 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 463 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02719184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02719184 about?
NCT02719184 is a clinical study titled "Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)". The study will include 60 healthy subjects (ex-smoker without any airflow limitation), 125 COPD GOLD (global initiative for chronic obstructive lung disease) I , 125 COPD GOLD II, 125 COPD GOLD III and up to 20 patients with COPD and A1AT (Alpha1-Antitrypsin) deficiency (ZZ genotype). Soluble and im...
What is the current status of trial NCT02719184?
This trial is currently completed. The enrollment target is 463 participants. The study started on 2016-04-13. Estimated completion is 2021-06-14.
Who is sponsoring clinical trial NCT02719184?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.